Compass Therapeutics announced positive Phase 2/3 COMPANION-002 trial results for tovecimig combined with paclitaxel in advanced biliary tract cancer (BTC). The study met its primary endpoint with an 18% response rate versus 5.3% for paclitaxel alone, and a 56% reduction in disease progression risk. The combination also improved disease control and showed durable responses. Safety was consistent with expectations, and further analyses are ongoing. These results support tovecimig's potential as a new treatment option for BTC patients with limited therapies.
Compass Therapeutics' Phase 2/3 trial results for tovecimig in biliary tract cancer provide context for health sector activity. For readers following Health-sector US stocks on Pluang, as of Oct 24, 2026 14:41 WIB, out of 150 priced stocks, 44 rose and 105 fell. Notable movers include CTXR at USD 0.40 with a +8.79% change and 98% buy order activity, LQDA at USD 42.65 up 7.46%, and OSCR at USD 30.99 down 6.99%.
Interim results from the Phase 3 DASL-HiCaP trial show that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduces the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
Celcuity announced updated Phase 3 VIKTORIA-1 study results showing that gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved median progression-free survival (PFS) in HR+/HER2- advanced breast cancer patients wi...
Chainlink announced new integrations with GravityChain, reflectmoney, and theorem_markets to enhance blockchain interoperability. These integrations enable seamless token transfers across different blockchains and provide high-speed market data deliv...
Ethereum's deflationary advantage over Bitcoin is weakening as ETH burning rates have dropped sharply and annual supply growth nears Bitcoin's level. However, increased on-chain activity, including higher Ethereum Velocity, more active addresses, and...
